Nordson Corporation Completes Acquisition of Atrion Corporation

Rhea-AI Summary

Nordson (Nasdaq: NDSN) has completed the acquisition of Atrion , a leader in proprietary medical infusion fluid delivery and niche cardiovascular solutions. This strategic move expands Nordson's medical portfolio into new markets and therapies, supported by long-term secular growth trends. The acquisition, initially announced on May 28, 2024, aligns with Nordson's innovative precision technology focus and scalable growth framework.

Nordson will provide further details about the acquisition during its third quarter fiscal year 2024 webcast scheduled for Thursday, August 22, 2024, at 8:30 AM ET. The company, founded in 1954 and headquartered in Westlake, Ohio, leverages a direct sales model and applications expertise to serve global customers across consumer non-durable, medical, electronics, and industrial end markets.

Positive

• Expansion into new medical markets and therapies
• Alignment with long-term secular growth trends
• Strengthening of Nordson's medical portfolio
• Potential for increased market share in medical technology sector

Negative

• None.

Insights

Financial Analyst

Nordson's acquisition of Atrion marks a strategic expansion into new medical markets, potentially boosting its revenue streams and market share. This move aligns with the growing trend of consolidation in the medical device industry, as companies seek to diversify their portfolios and tap into high-growth segments.

The deal's financial impact remains undisclosed, but investors should watch for potential synergies and margin improvements in Nordson's upcoming earnings reports. The acquisition's success will hinge on Nordson's ability to integrate Atrion's operations efficiently and leverage its proprietary technologies to drive innovation and market penetration.

While this expansion could enhance Nordson's long-term growth prospects, investors should also consider the integration risks and potential short-term impacts on the company's balance sheet. The medical device market's regulatory environment and reimbursement landscape will be important factors to monitor as Nordson navigates this new territory.

Medical Research Analyst

Nordson's acquisition of Atrion is a strategic move into the high-growth medical infusion and cardiovascular markets. Atrion's expertise in proprietary fluid delivery systems could complement Nordson's existing medical portfolio, potentially leading to innovative product developments.

The medical infusion market is experiencing steady growth due to the rising prevalence of chronic diseases and an aging population. Atrion's niche cardiovascular solutions also position Nordson to capitalize on the increasing demand for minimally invasive procedures.

Investors should note that success in these markets requires continuous R&D investment and navigating complex regulatory pathways. Nordson's ability to leverage Atrion's intellectual property and integrate it with their own technologies will be important for long-term value creation in this competitive landscape.

WESTLAKE, Ohio--(BUSINESS WIRE)-- Nordson Corporation (Nasdaq: NDSN) (the “Company” or “Nordson”) has completed the acquisition of Atrion Corporation (“Atrion”), a leader in proprietary medical infusion fluid delivery and niche cardiovascular solutions. The completion of the transaction follows the Company’s May 28, 2024 announcement that it had entered into an agreement to acquire the business. This acquisition will expand Nordson’s medical portfolio into new markets and therapies, supported by long-term secular growth trends.

The Company will provide comments about the acquisition in its previously announced third quarter fiscal year 2024 webcast, which is scheduled for:

Date: Thursday, August 22, 2024
Time: 8:30 AM ET
Link to listen: https://events.q4inc.com/attendee/410848164

Investors who are interested in listening to the webcast, but are not able to participate during the scheduled time, can access the replay by visiting Nordson’s investor website.

Nordson Corporation is an innovative precision technology company that leverages a scalable growth framework through an entrepreneurial, division-led organization to deliver top tier growth with leading margins and returns. The Company’s direct sales model and applications expertise serves global customers through a wide variety of critical applications. Its diverse end market exposure includes consumer non-durable, medical, electronics and industrial end markets. Founded in 1954 and headquartered in Westlake, Ohio, the Company has operations and support offices in over 35 countries. Visit Nordson on the web at www.nordson.com, www.twitter.com/Nordson_Corp or www.facebook.com/nordson.

Certain statements contained in this release are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by terminology such as “may,” “will,” “should,” “could,” “expects,” “anticipates,” “believes,” “projects,” “forecasts,” “outlook,” “guidance,” “continue,” “target,” or the negative of these terms or comparable terminology. These statements reflect management’s current expectations and involve a number of risks and uncertainties. These risks and uncertainties include, but are not limited to, U.S. and international economic conditions; financial and market conditions; currency exchange rates and devaluations; possible acquisitions, including the Company’s ability to successfully integrate acquisitions; the Company’s ability to successfully divest or dispose of businesses that are deemed not to fit with its strategic plan; the effects of changes in U.S. trade policy and trade agreements; the effects of changes in tax law; and the possible effects of events beyond our control, such as political unrest, including the conflict between Russia and Ukraine, acts of terror, natural disasters and pandemics, including the recent coronavirus (COVID-19) pandemic and the other factors discussed in Item 1A (Risk Factors) in the Company’s most recently filed Annual Report on Form 10-K and in its Forms 10-Q filed with the Securities and Exchange Commission, which should be reviewed carefully. The Company undertakes no obligation to update or revise any forward-looking statement in this press release.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240820967155/en/

Lara Mahoney

Vice President,

Corporate Communications & Investor Relations

440.204.9985

Lara.Mahoney@nordson.com

Source: Nordson Corporation

FAQ

When did Nordson complete the acquisition of Atrion ?

Nordson completed the acquisition of Atrion as announced in the press release. The exact completion date is not specified, but it occurred after the initial announcement on May 28, 2024.

What are the main products or solutions offered by Atrion ?

Atrion is a leader in proprietary medical infusion fluid delivery and niche cardiovascular solutions.

How will the Atrion acquisition impact Nordson's business (NDSN)?

The acquisition will expand Nordson's medical portfolio into new markets and therapies, supported by long-term secular growth trends. This is expected to strengthen Nordson's position in the medical technology sector.

When will Nordson (NDSN) provide more details about the Atrion acquisition?

Nordson will provide comments about the acquisition during its third quarter fiscal year 2024 webcast, scheduled for Thursday, August 22, 2024, at 8:30 AM ET.